[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360254-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360254-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-antibody-cocktail-therapy-targeting-extracellular-tumor-specific-mutations-to-treat-emt6-cell-line-derived-triple-negative-breast-cancer","Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancer","","Triple-negative breast cancer has limited treatment options and often resists therapy due to extensive tumor heterogeneity. Using the murine EMT6 cell line as a model, investigators generated polyclonal antibodies against 12 EMT6-specific mutated cell surface proteins, identifying nine that bound cumulatively without non-tumor binding. A 9-antibody cocktail combined with anti-PD-1 delayed tumor growth and improved survival in EMT6 tumor-bearing mice. Cancer Genome Atlas analyses showed many patients carried more than 10 such targets, supporting in vivo eradication of heterogeneous tumor cell populations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-antibody-cocktail-therapy-targeting-extracellular-tumor-specific-mutations-to-treat-emt6-cell-line-derived-triple-negative-breast-cancer/360254/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-antibody-cocktail-therapy-targeting-extracellular-tumor-specific-mutations-to-treat-emt6-cell-line-derived-triple-negative-breast-cancer/360254.png","ImageObject",300,407,{"name":42,"@type":43},"Adam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is triple-negative breast cancer difficult to treat in this research?","Question",{"text":63,"@type":64},"The document notes that treatment options for TNBC are limited and that tumor heterogeneity contributes to therapeutic resistance and recurrence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the EMT6-specific antibodies selected for the cocktail?",{"text":68,"@type":64},"Researchers produced polyclonal antibodies against 12 EMT6-specific mutated cell surface proteins and selected nine that bound EMT6 cells cumulatively without detectable non-tumor binding.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the impact of combining the antibody cocktail with anti-PD-1?",{"text":72,"@type":64},"In EMT6 tumor-bearing mice, the combination delayed tumor growth and improved survival compared with limited approaches alone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360254,1790641444,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nNovel antibody cocktail therapy targeting extracellular tumorspecific mutations to treat EMT6 cell line-derived triple-negative breast cancer  \nStephanie C. Pero1, Girja S. Shukla1, Yujing Sun1, Ramiro Barrantes-Reynolds2,  \nColin J. Hartman3, Margaret E. Ackerman3, Linda Mei1, Fan Zhang4, Matthew R. Fournier1 & David N. Krag1,5􀀍  \nTreatment options for triple-negative breast cancer (TNBC) remain limited, and the highly heterogeneous nature of these tumors often contributes to therapeutic resistance. While we have previously demonstrated that antibodies targeting multiple distinct mutated cell surface proteins (MSPs) unique to a given tumor can disrupt tumor growth in mice, the feasibility of this approach inTNBC remains uncertain. Here, we used the murine EMT6 cell line to model TNBC and produced polyclonal antibodies (pAbs) targeting 12 different EMT6-specific MSPs. Of these, 9 bound to EMT6 cells in a cumulative manner without detectable non-tumor binding. Administering a cocktail of these 9 MSP-targeting pAbsto EMT6 tumor-bearing mice in combination with anti-PD-1 delayed tumor growth and improved survival. Analyses ofTNBC patients in The Cancer Genome Atlas revealed that the tumors of a larger proportion of these patients harbored > 10 MSPs as compared to individuals with other breast cancer types (69% vs. 42%). Together, these results highlight the promise of using antibodies directed against MSPs expressed by TNBC tumor cells to kill tumor cells in vivo, providing a unique approach to individualized cancer patient care with the potential to achieve superior patient outcomes through the elimination of heterogeneous tumor cell populations.  \nKeywords Triple-negative breast cancer, Mutated cell surface protein-targeting antibodies, Somatic missense mutation, Antibody-dependent cellular cytotoxicity, Tumor growth inhibition  \nTumor growth entails the acquisition of additional mutations and the consequent emergence of increasingly heterogeneous cell populations1,2. Even when available treatments achieve a clinical complete response, the expansion of small populations of treatment-resistant tumor cells often leads to recurrence and drug resistance following successful treatment3–5, which is a persistent challenge to effective breast cancer management6. While recent combination regimens have conferred survival advantages to subsets of breast cancer patients with recurrent disease7–9, they have not fully resolved the underlying challenge of drug resistance. This is a particularly pressing clinical challenge for patients with triple-negative breast cancer (TNBC) for whom fewer treatment options are available. In the neoadjuvant setting, patients with TNBC exhibit a higher rate of complete response with the addition of checkpoint inhibitors, but incomplete tumor eradication remains a problem10. Targeted immune therapies, including monoclonal antibodies, vaccines, and T-cell therapies, must therefore be capable of overcoming tumor heterogeneity to contribute to better patient outcomes.  \nWe have focused on addressing the challenge of intratumoral heterogeneity by leveraging the firmly established ability of immune effector cells to clear antibody-opsonized target cells11, 12. TNBC patients lack any universal surface markers that can be safely and effectively targeted with therapeutic antibodies in a manner akin to the  \n1Department of Surgery, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, 05405 Burlington, VT, USA. 2Vermont Integrative Genomics Resource DNA Facility, University of Vermont, Burlington, VT, USA.  \n3Thayer School of Engineering, Dartmouth College, Hanover, NH, USA. 4The Vermont Biomedical Research Network, University of Vermont, Burlington, VT, USA. 5Moonshot Antibodies, Inc , Shelburne, USA. 􀀍 email: [david.krag@med.uvm.edu](david.krag@med.uvm.edu)  \n[www. nature.com/scientificreports/](www. nature.com/scientificrep","cbCairNlbUuDmEw0","https://ap.wps.com/l/cbCairNlbUuDmEw0","pdf",2965387,13,"English","# Abstract\n## Antibody cocktail design and binding assessment\n## Therapeutic effects in EMT6 tumor-bearing mice\n## Human target prevalence and clinical relevance","[{\"question\":\"Why is triple-negative breast cancer difficult to treat in this research?\",\"answer\":\"The document notes that treatment options for TNBC are limited and that tumor heterogeneity contributes to therapeutic resistance and recurrence.\"},{\"question\":\"How were the EMT6-specific antibodies selected for the cocktail?\",\"answer\":\"Researchers produced polyclonal antibodies against 12 EMT6-specific mutated cell surface proteins and selected nine that bound EMT6 cells cumulatively without detectable non-tumor binding.\"},{\"question\":\"What was the impact of combining the antibody cocktail with anti-PD-1?\",\"answer\":\"In EMT6 tumor-bearing mice, the combination delayed tumor growth and improved survival compared with limited approaches alone.\"}]","Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancer | PDF",1790139314,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bce48e4660f97b362957dd14bd9280d2.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42324fe41dbbd4454db648495010690b.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70539f83e2ad5398a2666f90db24f0bf.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b120be3f647ba1349a693c6a53df30f.webp",980,1287]